https://de.marketscreener.com/kurs/aktie/BIOPHYTIS-S-A-22837372/news/Biophytis-SA-startet-mit-BIO101-20-Hydroxyecdyson-die-klinische-Phase-2-Studie-OBA-zur-Behandlung-46394804/?utm_source=telegram&utm_medium=social&utm_campaign=share